Sonoyama Wataru, Coppe Carolyn, Gronthos Stan, Shi Songtao
Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA.
Curr Top Dev Biol. 2005;67:305-23. doi: 10.1016/S0070-2153(05)67010-X.
Postnatal stem cells have been isolated from a variety of tissues and they are highly expected to have potentiality to be utilized for cell-based clinical therapies. Bone marrow stromal stem cells (BMSSCs) derived from bone marrow stromal tissue have been identified as a population of multipotent mesenchymal stem cells that are capable of differentiating into osteoblasts, adipocytes, chondrocytes, muscle cells, and neural cells. The most significant tissue regeneration trait of BMSSCs is their in vivo bone regeneration capability, which has been widely studied for understanding molecular and cellular mechanisms of osteogenesis, and, more importantly, developing into a stem-cell-based therapy. Recent studies further demonstrated that BMSSC-mediated bone regeneration is a promising approach for regenerative medicine in clinical trials. However, there are some fundamental questions that remain to be answered prior to successful utilization of BMSSCs in clinical therapy. For instance, how to maintain stemness of BMSSCs will be a critical issue for developing methodologies to propagate multi-potential stem cells in vitro, in order to allow the development of effective clinical therapies.
产后干细胞已从多种组织中分离出来,人们高度期望它们具有用于基于细胞的临床治疗的潜力。源自骨髓基质组织的骨髓基质干细胞(BMSSCs)已被鉴定为一群多能间充质干细胞,能够分化为成骨细胞、脂肪细胞、软骨细胞、肌肉细胞和神经细胞。BMSSCs最显著的组织再生特性是其体内骨再生能力,这已被广泛研究以了解成骨的分子和细胞机制,更重要的是,发展成为基于干细胞的治疗方法。最近的研究进一步表明,BMSSC介导的骨再生是临床试验中再生医学的一种有前景的方法。然而,在临床治疗中成功利用BMSSCs之前,仍有一些基本问题有待解答。例如,如何维持BMSSCs的干性将是开发体外扩增多能干细胞方法的关键问题,以便开发有效的临床治疗方法。